"Study reveals low treatment rates among MS patients in the UK"
A new study reveals that people with multiple sclerosis (MS) in the UK are less likely to be on disease-modifying treatments (DMTs) compared to MS patients in other European countries. The study suggests that tighter checks in the UK for accessing DMTs through the National Health Service (NHS) may be a contributing factor. The research highlights the need for improved access to neurologists and MS specialists in the UK to enhance the treatment landscape and quality of life for MS patients. The study also found differences in DMT usage across Europe, with Sweden having the highest rates of DMT use. The findings emphasize the importance of early treatment with DMTs to improve long-term health and well-being for people living with MS.